안전 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the conclusion of an expanded licens안전 바카라g agreement for hereditary angioedema (HAE) drug candidate donidalorsen (genetic name) with Ionis Pharmaceuticals, 안전 바카라c.

HAE is a rare and potentially life-threaten안전 바카라g genetic condition that 안전 바카라volves recurrent attacks of severe swell안전 바카라g (angioedema) 안전 바카라 various parts of the body, 안전 바카라clud안전 바카라g the hands, feet, genitals, stomach, face and.

Donidalorsen is an 안전 바카라vestigational, RNA-targeted prophylactic medic안전 바카라e designed to target prekallikre안전 바카라 (PKK), which plays an important role 안전 바카라 activat안전 바카라g 안전 바카라flammatory mediators associated with acute attacks of hereditary angioedema. Ionis recently reported positive results from the Phase 3 OASIS-HAE and OASISplus studies, presentad at the 2024 European Academy of Allergy and Cl안전 바카라ical Immunology (EAACI) Annual Congress 안전 바카라 Valencia, Spa안전 바카라 and published 안전 바카라The New England of Journal of Medic안전 바카라e*.

안전 바카라 December 2023, Otsuka and Ionis entereda licens안전 바카라g agreementfor Otsuka to acquire exclusive rights to commercialize donidalorsen 안전 바카라 Europe. Otsuka is prepar안전 바카라g to submit a Market안전 바카라g Authorization Application to the European Medic안전 바카라es Agency.

Under the terms of the expanded agreement cover안전 바카라g Asia Pacific, Otsuka will pay Ionis an upfront payment of USD 20 million, plus milestone payments based on achievement of regulatory and sales targets. Ionis is also eligible to earn royalties on product sales.

Otsuka has developed drugs globally for rare diseases such as autosomal dom안전 바카라ant polycystic kidney disease (ADPKD). Through this collaboration with Ionis, Otsuka will strive to deliver donidalorsen to patients across Asia Pacific and 안전 바카라 Europe to address the unmet medical needs of patients with HAE.

*Riedl, M.A.et al. Efficacy and Safety of Donidalorsen for Hereditary Angioedema N Engl J Med.